Articles tagged with Cancer Medication
Researchers developed a handheld, portable device that can detect Kaposi sarcoma-associated herpesvirus (KSHV) with 94% accuracy in resource-limited settings. The Tiny Isothermal Nucleic acid quantification sYstem (TINY) generates results in under 2.5 hours, enabling early detection and better outcomes.
A new AI program can analyze lung tumor images to specify cancer types and identify genetic changes, offering a potential solution for faster diagnosis and treatment. The tool achieved high accuracy rates in distinguishing between adenocarcinoma and squamous cell carcinoma, as well as identifying altered genes linked to lung cancer.
A landmark study of over 19,000 participants aged 70+ found that taking low-dose aspirin daily does not prolong life free of disability or significantly reduce the risk of heart attacks and strokes. The study also showed an increased risk of serious bleeding among aspirin-takers.
A new method developed by University of Copenhagen researchers, His-tag acylation, allows for precise targeting of proteins, reducing the risk of side effects. The approach enables the creation of tailored pharmaceuticals with enhanced characteristics, such as tracking proteins' path through cells.
A recent study published in Journal of Internal Medicine found that adhering to an anti-inflammatory diet was associated with lower risks of dying from any cause, cardiovascular causes, and cancer. Participants who closely followed the diet had an 18% lower risk of all-cause mortality compared to those who followed it to a lesser degree.
An analysis of UK newspaper reporting on the NHS Cancer Drugs Fund found mostly positive but uncritical stories, potentially misleading the public about the fund's benefits. The study suggests that media coverage contributed to a strong perception that expensive new medicines are the best way to help cancer patients.
A study found that Medicaid expansion under the ACA did not increase access to complex surgeries at high-volume hospitals among ethnic/racial minorities and low-income populations. Despite overall increased surgical care access, disparities in complex surgery utilization persisted.
A study published in PLOS Pathogens identified three new molecular drug targets for the treatment of primary amebic meningoencephalitis. The researchers found that certain cancer drugs, such as tamoxifen and Prozac, are effective against the brain-eating amoeba Naegleria fowleri.
Researchers found that while severe reactions can occur, the risks are low compared to common cancer treatments. The study identified a peak timing for fatal toxicities within 15-40 days after treatment initiation, depending on the type of immune checkpoint inhibitor.
Researchers and regulators have conducted an expedited analysis of recalled blood pressure drugs, finding no association between use of potentially contaminated products and increased short-term cancer risk. However, a slightly increased risk of colorectal and uterine cancers was found in patients exposed to the impurity NDMA.
A new study by UCSF researchers reveals that nearly one in seven older veterans with hypertension are discharged with increased blood pressure medications despite having well-controlled blood pressure prior to their hospital stay. The study suggests a potential risk of medication harm due to overtreatment, particularly among older adults.
A DNA-based analysis can predict likelihood of disease recurrence in MDS patients after a stem cell transplant, helping doctors guide treatment decisions. The test identifies mutations before and after transplantation to detect residual cancer cells.
Researchers found that EVL protein helps contain cancer cells within the original tumor site by regulating actin cytoskeleton, which may lead to combination treatments for patients with ER-positive tumors.
Researchers at University of Houston develop synthetic compound that inhibits two major pathways of pancreatic cancer. The drug, MA242, targets NFAT1 and MDM2, reducing tumor growth and progression.
A new study published in JAMA found that immediately reducing nicotine in cigarettes leads to more rapid positive public health effects, including decreased exposure to toxic chemicals and increased smoke-free days. However, smokers may experience more severe withdrawal symptoms during the transition.
The new study reveals that different KRAS mutations have distinct effects on the KRAS protein's molecular-level function. The findings enhance understanding of cancer-causing mutations and may lead to the development of targeted drug therapies.
A widely used drug has been identified as a contributor to skin cancer development, with researchers calling for enhanced sun protection advice. The study, published in Nature Communications, found a strong association between azathioprine use and a specific mutational signature in cutaneous squamous cell carcinoma.
A new study analyzed data from two UK and US centers to find that patients with advanced lung cancer often receive multiple medications that may not be beneficial. On average, these patients were prescribed 1.9-2.6 preventative medications at admission and discharge. The authors suggest developing an intervention to reduce inappropriat...
The 2018 Dr. Paul Janssen Award Symposium will highlight recent advances in immuno-oncology and innovative strategies for optimizing cancer treatment. James P. Allison, PhD, will receive the award for his leading role in developing ipilimumab, a first immune checkpoint inhibitor approved by the FDA.
A clinical study using the CURATE.AI platform successfully treated a patient with metastatic castration-resistant prostate cancer, completely halting disease progression. The AI platform continuously optimised novel drug combination dosages to achieve a durable response, allowing the patient to resume an active lifestyle.
A researcher has linked the mysterious illness affecting American and Canadian diplomats in Cuba and China to radiofrequency/microwave radiation. The study's findings may aid in treating affected individuals and shed light on a larger population of people experiencing similar health problems.
Researchers at Hong Kong Baptist University have developed a metal compound that inhibits the enzyme lysine-specific demethylase 5A (KDM5A) in TNBC tumours with less toxicity in mice. This discovery holds great promise for the development of targeted drugs for TNBC therapy, offering a new approach to treating this difficult form of bre...
Researchers identified six classes of genes that contribute to cancer resistance, including CDK4/6 inhibitors. Combining BET and CDK4/6 inhibitors completely stopped tumors from growing in preclinical experiments.
Researchers at Mount Sinai discovered that stromal cells in bladder cancer tumors prevent immune cells from attacking them, leading to low response rates with PD-1/PD-L1 inhibitors. The study identified genes linked to more aggressive cancers and found that tumors with these genes were less responsive to treatment.
A study by researchers at the University of Cincinnati found that cell metabolism significantly influences autophagy, a survival program used by some tumor cells to evade treatment. The findings suggest that manipulating this pathway could lead to better cancer treatments and outcomes.
A UCLA-led study found that a combination of pembrolizumab and SD-101 can alter the tumor microenvironment, enabling the immune system to attack cancer more effectively. The treatment has shown promise in people receiving immunotherapy for the first time, with some patients experiencing complete tumor disappearance.
Research from the University of Sydney shows that high-quality medication reminder apps increase people's adherence to cardiovascular medication. A clinical trial found no additional benefits from advanced features like snooze reminders and social support structures.
Researchers at Hebrew University of Jerusalem have developed a new biological drug that has shown a 50% cure rate in lab mice with acute leukemia. The single-molecule drug targets multiple leukemic proteins, making it difficult for cancer cells to evade therapy and reducing the need for multiple treatments.
University of Bristol researchers have discovered a way to exploit hypoxia to kill cancer cells without harming healthy tissue. The study found that a specific receptor, GPRC5A, can be targeted using genetic techniques to trigger cancer cell death.
Scientists have created a more complete humanized mouse model by combining human hematopoietic stem and progenitor cells with mesenchymal stem cells. This allows for more realistic testing of immunotherapies, leading to improved cancer treatment predictions. The new model enables researchers to compare the interaction of the immune sys...
A new cancer drug lead, C1, has shown promise in reducing tumor size by forcing tumors back to normal metabolism. The approach combines two existing drugs, doxorubicin and dichloroacetic acid, to deliver a potent toxin and prevent tumor growth.
Researchers have developed a new class of anti-cancer medicines based on nanoMIPs, which selectively bind to specific molecular targets. This approach ensures high specificity and stability over temperature and acidity, expanding treatment options for various diseases.
Effective medical treatment and surgery prevent esophageal cancer in people with severe heartburn. The study used health data from 1964 to 2014 and found a significant decrease in cancer risk after treatment.
Researchers have developed a new drug that targets EBV-positive tumors and inhibits tumor development and metastases for EBV-related lymphomas. The findings suggest the drug may be useful in treating malignancies in EBV-positive patients.
Scientists at Salk Institute and Purdue University discovered a key to mass-producing beneficial plant compounds, including terpenoids used in fragrances, flavorings, biofuels, and pharmaceuticals. They found that plants have an
The new ESCAT grading system helps distinguish between tumour DNA alterations relevant for targeted medicine decisions and those that aren't. The system enables clinicians to prioritize mutations and make data-driven treatment choices.
Researchers create universal platform using magnetite-gold particles for targeted cancer treatments and simultaneous diagnosis. The breakthrough discovery enables therapeutic delivery of drugs to tumor cells while detecting them with magnetic resonance imaging.
A phase 1 clinical trial at the University of Colorado Cancer Center has shown promising results, with 72% 2-year survival in heavy smokers. The combination of olaparib, cetuximab, and radiation was found to be synthetically lethal for cancer cells, leading to enhanced cell death.
Researchers at Washington State University discovered that cancer-fighting drugs can slow or stop fungal infections in plants by activating genes used to defend against pathogens. The study showed two different results from the applications of DNA-specific drugs on pea tissue, with differing mechanisms of action.
Scientists have created specialized delivery methods using nucleic acid-based nanostructures to target cancer cells while leaving normal cells intact. The new approach utilizes aptamers to bind to specific receptors on cancer cells, allowing for the targeted delivery of chemotherapeutic drugs.
A novel approach targeting the RAS / MAP Kinase pathway slows cancer growth in lung, skin, colon, and pancreatic cancers. Researchers have identified a compound that effectively decouples the entire pathway from external growth signals, leading to significant inhibition of cancer growth.
Researchers at Penn Medicine discovered PARP inhibitors could prevent toxic TDP-43 accumulations in brain cells. The treatment shows promise for neurodegenerative disorders like ALS and FTD.
A new cancer therapy using nanoparticles could deliver a double blow to cancer by making breast and prostate tumours more sensitive to chemotherapy, reducing toxicity risks. The therapy combines two approved drugs, docetaxel and fingolimod, targeting cancer cells with reduced side effects.
A new study suggests that cancer treatment should be viewed as a game where physicians can exploit their knowledge of the cancer's evolutionary dynamics to develop flexible strategic treatment plans. By continuously adjusting drugs and doses, physicians can delay or prevent cancer progression caused by resistance.
Researchers discovered a previously unrecognized mechanism by which arsenic trioxide and all-trans retinoic acid work together to destroy Pin1, a unique enzyme that activates over 40 cancer-driving proteins. This finding suggests novel strategies to treat common cancers, including triple-negative breast cancer.
Researchers identify MUC5AC gene as a key player in KRAS-mutant non-small cell lung cancers, which are resistant to current treatments. Inhibiting this gene may lead to new therapeutic strategies against KRAS-driven lung cancer.
Researchers at SwRI and UTSA are developing a biodegradable implant that can deliver personalized doses of medicine to treat various illnesses. The implant is designed to be drug agnostic and can work with any type of drug, potentially treating a wide range of diseases.
Nanoparticles have been modified to be absorbed through the lymphatic system, increasing bioavailability seven-fold. The new technique uses glycocholic acid as a cloak to help nanoparticles slip incognito through the small intestine lining.
A new RNA sequencing platform has been developed to match thousands of drugs with late-stage and drug-resistant multiple myeloma patients, providing a more accurate treatment approach. The platform's results showed that a majority of patients benefited from personalized treatment plans based on their cancer's RNA profile.
Researchers developed a new sensor that detects hydrogen peroxide levels in human cells to identify effective chemotherapy drugs. The sensor can be used to screen existing drugs and predict success in individual patients' tumors. This breakthrough could lead to more targeted and effective cancer treatments.
A new method has been developed to deliver curcumin to cancer cells, enhancing its effectiveness in treating various cancer types. The approach involves creating a sophisticated metallocyclic complex using platinum that increases curcumin's solubility and synergy.
A research team has developed a novel peptide drug called FFW that shows promise in reducing tumour growth and slowing down the spread of cancer cells. The drug targets SALL4 protein interactions, previously considered undruggable, and has shown effective results in lab experiments.
Researchers found that thalidomide acts by promoting the degradation of transcription factors, including SALL4, leading to limb and fetal growth complications. The study's findings will help guide development of new anticancer drugs with a similar scaffold.
Researchers have discovered a novel way to enhance targeted cancer drugs by testing cocktail combinations on human cancer cell lines, fruit flies, and mice. The findings suggest that these cocktail combinations can be used with targeted therapy drugs or after failed attempts.
Senescent cells, also known as 'zombie cells,' interfere with tissue function and contribute to aging diseases. Researchers have designed a nano-carrier that selectively targets these cells, releasing drugs to kill them and improving therapeutic outcomes in pulmonary fibrosis and cancer models.
Researchers discovered a new lead compound that could improve existing treatments for cancer, diabetes and obesity. The study identified the HDAC11 enzyme as a crucial target for developing new drugs.
Researchers at the Weizmann Institute of Science have developed a new combination therapy using three drugs to block growth from without and within, potentially relieving resistance in lung cancer patients. The approach was successful in mice and may help extend the lives of thousands of lung cancer patients.
Researchers identified Shieldin, a protein complex that regulates DNA repair and may explain why some patients develop resistance to new anti-cancer drugs. The study's findings suggest that Shieldin levels can be used as a marker for identifying patients likely to respond poorly to PARP inhibitors.
Researchers found that patients using complementary medicine had a higher risk of death and were more likely to refuse conventional cancer treatments. The study analyzed data from over 1,290 patients with breast, prostate, lung, or colorectal cancer.
A team of researchers has uncovered a new protein complex called Shieldin that plays a critical role in normal cell division and cancer treatment. The complex shields broken DNA ends and controls the type of DNA repair system used by cells, making it vulnerable to targeting by PARP inhibitors and platinum-based chemotherapies.